News

The open label trial is being conducted by the NCIC Clinical Trials Group (NCIC CTG), Queen’s University in Kingston, Canada. Oncothyreon president and CEO Robert Kirkman said the

The four-year collaboraton will primarily focus on investigating three cell types expected to add to the onset of obesity and diabetes due to their dominant role in metabolic

The test system supports on-site lipid panel screening, which includes total cholesterol, HDL cholesterol, triglycerides, and LDL (calculated) along with glucose and provides the results in less than

OMS824 targets and inhibits an enzyme expressed in areas of the brain associated with diseases that affect cognition, including schizophrenia and Huntington’s disease, PDE10. Omeros chairman and chief

Sym004 is comprised of two antibodies designed to block ligand binding, receptor activation and downstream signaling and to draw out removal of the EGFR receptors from the cancer

The company has translated the language to meet Health Canada requirements for consumer product sales through the assistance of Lionbridge Technologies and modified the original Health Canada application

The transaction, which values Medicis’s common stock nearly $2.6bn, was approved by the Boards of Directors of both companies. Valeant’s chairman and chief executive officer Michael Pearson said

ATX-101, a injectable facial aesthetic drug under clinical investigation for the reduction of submental fat, is a proprietary formulation of synthetic sodium deoxycholate, a well-characterised component of human

AVP-923 is a combination of the active ingredient dextromethorphan hydrobromide and low dose quinidine sulfate, which serves to increase the bioavailability of dextromethorphan, the ingredient active in the